Understanding beta cell disorders through genetic insights
Official title: Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE)
Run by University of Exeter · NCT06478121 · Data updated 2026-11-12
This study is trying to learn more about beta cell problems, like diabetes, by looking at the genes of people with and without these issues to see if it can help find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years to 99 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Exeter Academic / other |
| Locations | 1 site (Exeter, Devon) |
| Status | Recruiting |
| Started | November 11, 2025 |
| Main results expected | February 28, 2029 |
| Study ends | February 28, 2029 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06478121 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with confirmed genetic variants causing beta cell disorders and matched controls without such variants.
✕Probably not a fit
Patients without a genetic variant related to beta cell disorders or those outside the specified age range may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on understanding the cellular and molecular mechanisms behind beta cell disorders, such as diabetes and hyperinsulinism, by recruiting participants based on their genetic variants. Individuals with and without pathogenic genetic variants will be analyzed to identify biomarkers and cellular features linked to these disorders. Participants will undergo data collection, height and weight measurements, blood sampling, and optional MRI scans, depending on their genotype. The study aims to enhance the understanding of beta cell function and potentially lead to new treatment strategies for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and better management strategies for patients with beta cell disorders.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in understanding genetic contributions to metabolic disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Mental capacity to give informed consent * Of any sex, ethnicity, location. * Group 1: Cases will have a genetic variant(s) resulting in a beta cell disorder. * Group 2: Controls will not have a genetic variant(s) resulting in a beta cell disorder and will be matched to a Case for sex, age (+/- 15%) and BMI (+/- 3 kg/m2). Exclusion Criteria * Lack of mental capacity to give informed consent * Age \<6 years; \>99 years Additional exclusions for MRI assessments: * Cochlear Implant * Aneurysm Clips * Neurological stimulator * Implanted cardiac devices (ICD, PPM, loop recorders, or any others) * Metal heart valve * History of metal foreign bodies in orbits * Other implanted metal device which prevents MRI * Known claustrophobia.
Where it's running
-
Royal Devon University Healthcare NHS Foundation Trust
Exeter, Devon, United Kingdom Recruiting
Study contacts
- Principal investigator: Andrew Hattersley, FRS, FMed — University of Exeter
- Study coordinator: Matthew Johnson, PhD
- Email: m.johnson@exeter.ac.uk
- Phone: +44 (0) 1392 408277
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dorzagliatin for glucokinase (GCK-MODY) diabetes
This trial will test whether dorzagliatin, a drug that activates glucokinase, can lower blood sugar in adults with GCK-MODY caused by an inactivating GCK mutation.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.